Chemotherapy drugs made by Indian firms fail quality checks, shows study

Vital chemotherapy drugs used around the globe have failed quality checks, leaving most cancers sufferers in additional than 100 international locations prone to ineffective therapies and probably deadly unintended effects, the Bureau of Investigative Journalism (TBIJ) can reveal.

The drugs in query type the spine of remedy plans for quite a few widespread cancers – together with breast, ovarian and leukaemia. Some drugs contained so little of their key ingredient that pharmacists stated giving them to sufferers can be nearly as good as doing nothing. Other drugs, containing an excessive amount of lively ingredient, put sufferers prone to extreme organ injury and even demise. “Both scenarios are horrendous,” stated one pharmacist. “It’s heartbreaking.” 

Doctors from a number of international locations informed TBIJ of the drugs in query not working as anticipated, leaving sufferers instantly unresponsive to remedy. Other sufferers suffered unintended effects so poisonous that they might not tolerate the medication. 

The variance discovered within the ranges of lively ingredient was alarming. In some circumstances, capsules from the identical blister pack contained completely different quantities.

These findings expose large holes within the international security nets meant to stop profit-seeking producers from chopping corners, and to guard sufferers from unhealthy drugs. All the whereas, sufferers and governments with stretched assets are paying the value for drugs that don’t work.

A worldwide killer

Cancer is among the largest killers worldwide, linked to round 10 million deaths yearly – roughly one in six. The burden of most cancers is rising, significantly in low- and middle-income areas. In sub-Saharan Africa, for instance, cases of most cancers have doubled within the final 30 years. 

Much of the worldwide demand for remedy is met by so-called generic drugs. These are variations of a drug that may be made as soon as the unique maker’s exclusivity rights have expired, and are usually made much more cheaply. The unhealthy drugs described on this investigation have been all generics. 

Generics are extensively utilized in all international locations however are most vital in these with fewer assets, the place costlier therapies could be past attain. If generics weren’t accessible in sub-Saharan Africa, for example, “any cancer treatment would be likely inaccessible to most of the population”, stated Claudia Martinez of the Access to Medicine Foundation*, an NGO.

In chemotherapy drugs, the lively ingredient – which fights most cancers cells – can also be extremely poisonous. Patients must obtain sufficient of it to deal with the most cancers however not a lot that they overdose and endure damaging unintended effects. As such, hospital pharmacists calculate doses rigorously – and in doing so, depend on the quantity of lively ingredient being precisely what’s said on the label.

Research from a landmark study revealed immediately examined the quantity of lively ingredient in seven widespread varieties of most cancers drug: cisplatin, cyclophosphamide, doxorubicin, ifosfamide, leucovorin, methotrexate and oxaliplatin. All of them are classed as important medicines by the World Health Organisation (WHO).

Working with collaborators in Cameroon, Ethiopia, Kenya and Malawi, researchers on the University of Notre Dame, Indiana, analysed drug samples from the 4 international locations. 

Of 189 samples that had not expired on the time of testing, about one fifth failed. This consisted of 20 completely different manufacturers of generic drug made by 17 producers.

“We were all taken aback when we saw the results,” stated Marya Lieberman, the professor who led the analysis. 

More than 30 producers made merchandise to an excellent normal. But for sufferers receiving the poor-quality drugs, the consequences could possibly be devastating. “Once a person has been diagnosed with cancer, there’s a limited window of opportunity for treatment to work,” stated Lieberman. “And if someone is treated with an ineffective product, they can lose that precious window.”

The majority of failed drugs had too little lively ingredient (for many this meant lower than 88% of the quantity said on the label) whereas some contained an excessive amount of (greater than 112%). Both thresholds have been determined by researchers based mostly on worldwide requirements.

“Both scenarios are horrendous in my eyes,” stated Shereen Nabhani-Gebara, vice chair of the British Oncology Pharmacists Association. “It takes a lot of courage for someone with cancer to accept a diagnosis, but then to be short-changed like this when they are trying their best is heartbreaking – because this is someone’s life.”

Tracking the risk

Over the previous six years, these manufacturers of drugs have been shipped to greater than 100 international locations in each populated continent on the planet. They vary from low- and middle-income nations like Nepal, Ethiopia and North Korea, to rich international locations such because the US, UK and Saudi Arabia. 

The worst-performing drug within the study is made by Indian producer Venus Remedies. It is a drug referred to as cyclophosphamide, which is usually used to deal with cancers together with lymphoma and breast most cancers.

All eight samples of this Venus Remedies drug failed, with six containing lower than half the quantity of lively ingredient claimed by the producer. One contained simply over 1 / 4 of the said dose, which based on a number of most cancers pharmacists can be as efficient as no remedy in any respect.

The drug has been shipped to 6 international locations, with its largest importer being Ethiopia.

Wondemagegnhu Tigeneh, a medical oncologist within the Ethiopian capital Addis Ababa, informed TBIJ that he has handled sufferers with chemotherapy drugs he believes didn’t work.

“I have a suspicion that the active ingredient was lower than expected,” he stated, remembering a drug he gave to a latest affected person who had responded properly to the primary three rounds of remedy. But on the subsequent spherical, their progress instantly stopped.

Because he has no means to check them, Tigeneh can by no means make certain of the quality of a given drug. But in his 20 years treating most cancers, he has realized to note tell-tale indicators. Sometimes, for example, there’s a full absence of side-effects akin to nausea or hair loss. “That makes it difficult to trust that particular drug,” he stated.

Then there are the sufferers whose illness he struggles to get below management, akin to a affected person whose response to remedy halted with out warning. Rather than decreasing the scale of the tumour sufficient to allow surgical procedure, his group has been pressured to maneuver onto a second-line remedy. If that fails, the subsequent stage is palliative care. “It’s very sad,” stated Tigeneh. “We didn’t used to see things like this.”

Cancer sufferers in Ethiopia have much better entry to remedy services now than they did 20 years in the past. It doesn’t appear, nevertheless, that the usual of medicines has stored tempo. A 2020 study of most cancers drugs in Ethiopia included 20 samples of cisplatin which have been all discovered to be substandard, averaging simply over half of the said content material. One researcher who checks the quality of drugs within the nation informed TBIJ that they discover unhealthy medicines wherever they go.

Venus Remedies informed TBIJ that the study outcomes have been “not scientifically plausible” given the corporate’s “validated manufacturing systems and quality controls.” It stated it has acquired no complaints or issues concerning the batches in query and shared the outcomes of its personal testing that indicated they have been of an excellent normal. 

It stated storage circumstances within the provide chain, which might have an effect on drug quality, may need affected the researchers’ check outcomes. However, the absence of comparable quality points throughout the complete knowledge set suggests this isn’t the case.

Venus Remedies is considered one of three firms or regulators that queried the methodology used by the lab, saying it deviated from worldwide requirements or might give inaccurate outcomes. However, Lieberman stated that, though her outcomes usually are not meant for regulatory functions, her researchers’ strategies are based mostly on these used by regulatory labs and have been verified for suitability, accuracy, and precision. Both the findings and strategies have been scrutinised by unbiased teachers.

Toxic results

Some 3,200 km south of Addis Ababa, in Malawi, specialist most cancers care has solely been accessible for round 15 years. In one of many poorest international locations on this planet, sufferers rely on healthcare being free on the level of want. That means clinics need to depend on generic drugs.

A pharmacist specialising in most cancers care in central Malawi informed TBIJ of seeing sufferers at his hospital overdose on methotrexate, a drug used to deal with leukaemia and lymphoma.

Malawi has additionally imported two of the manufacturers of methotrexate the researchers on this investigation discovered to comprise an excessive amount of lively ingredient: Zuvitrex, made by Zuvius Lifesciences, and Unitrexate, made by United Biotech. Neither firm responded to a number of requests for remark.

This type of extra will be simply as dangerous as a deficit. A nasty overdose can go away a affected person with lifelong unintended effects and even kill them. As Nabhani-Gebara stated: “More is not better.” 

The Malawian pharmacist stated sufferers at his hospital have suffered extreme vomiting and nausea after overdosing on methotrexate, whereas others needed to be moved onto a second-line remedy, which might not be as efficient. For some sufferers, the unintended effects have been so extreme that they needed to pause remedy fully – giving the most cancers an opportunity to develop.

When a pattern of the methotrexate in query was examined as a part of a analysis mission going down on the time, it was discovered to be too excessive in lively ingredient. “It’s very worrying,” the pharmacist stated.

He informed TBIJ that he and his colleagues have occasionally needed to cease utilizing a whole batch of chemotherapy medication and ship samples to the nationwide drug regulator after the medication modified color – an indication one thing is mistaken with it.

“We had patients scheduled for clinic,” he stated, “and then we had to break the news to them that we don’t have medicines.”

Failing security nets

Countries everywhere in the world have techniques in place to cease unhealthy drugs reaching sufferers. However, there are large disparities of their effectiveness. According to Chaitanya Kumar Koduri of the US Pharmacopeia, an organisation that units requirements for medicines within the US and internationally, “70% of countries cannot take care of their own medicine quality”.

Most governments have a nationwide regulator – however their remit and assets range massively. And even the better-funded regulators are removed from foolproof. The US Food and Drug Administration (FDA), for example, is struggling to maintain up with inspections of producing crops domestically and in India and China, and has admitted that its inspections haven’t been a dependable indicator of drug quality. 

The FDA lately introduced it could develop unannounced inspections at international manufacturing services, saying this may assist expose those that falsify data or cover violations.

It informed TBIJ “that inspections and reviews will continue to ensure [drug] safety and efficacy”.

One of the international locations the place medication regulation ranks the bottom, based on the WHO, is Nepal. It can also be one of many largest importers of the failed chemotherapy manufacturers on this investigation. 

Despite there being greater than 20,000 manufacturers of drugs available on the market there, the nation’s drugs regulator has set a goal of testing simply 22 drugs within the subsequent 12 months – and none of them chemotherapy drugs.

Narayan Prasad Dhakal, the regulator’s director normal, informed TBIJ that its lab can not presently check most cancers drugs and admitted that the state of affairs round quality-testing is “a concern”. He additionally stated that whereas his division has the facility to recall most cancers drugs based mostly on exterior proof, it has by no means executed so.

The subject is particularly fraught for sufferers who could have travelled from distant, rural areas to get remedy that then could not even work.

Laxmi Kumari, whose two-year-old son is being handled for most cancers in Kathmandu, Nepal’s capital, has needed to procure chemotherapy drugs from non-public pharmacies. The remedy has value the household practically two lakh rupees, equal to a number of months’ common wage in Nepal, and but they haven’t any reassurance that it is going to be efficient.

“We have no way of knowing the quality of the medications being used in his treatment,” stated Kumari. “We rely entirely on what the doctors recommend.”

“Neither patients nor their families have any way of knowing the quality of these drugs,” stated Smriti Pokharel of the Wish Nepal Foundation, which helps kids from low-income households entry most cancers remedy. 

“Even doctors face challenges in verifying their quality. No one seems willing to take responsibility for ensuring proper treatment for cancer patients.” 

Race to the underside

Generic drug producers are working in a worldwide market that healthcare professionals and consultants agree is pushed by one factor: worth. It’s a market through which these working below a much less watchful eye can discover methods to undercut their opponents. 

This might imply scrimping on the quantity or quality of the lively ingredient – the costliest element – or utilizing low cost or outdated equipment. Research shows that almost all of substandard drugs happen resulting from issues with manufacturing, quality management, packaging or storage.

The outcomes will be deadly. Four kids died in Colombia after being given contaminated most cancers drugs in 2019. Three years later, one other batch of unhealthy medication triggered the deaths of at the very least 10 kids in Yemen who have been being handled for leukaemia. 

The price-driven market creates a harmful dynamic through which the variety of firms making a selected drug shrinks and shrinks till international provide is precariously depending on only a handful of producers. Should one firm slip up, hundreds of sufferers will be left with out the drugs they rely on. 

It’s a state of affairs that performed out within the US lately. Between 2018 and 2022, Intas Pharmaceuticals – the father or mother firm of Accord Healthcare, which made the worst-performing cisplatin examined on this investigation – grew its market share of cisplatin from 24% to 62%. It additionally elevated its share in methotrexate fivefold in the identical time interval. All the whereas, costs of each these chemotherapy drugs dropped. 

Then on the finish of 2022, a shock inspection by the US drug regulator revealed a “cascade of failure” at an Intas manufacturing unit in India, the place workers have been seen shredding and pouring acid on quality data. The shutdown that ensued despatched shockwaves throughout the US, with practically each main most cancers centre reporting shortfalls in chemotherapy drugs through the spring or summer time of 2023, based on the New York Times.

Accord Healthcare stated the batch of cisplatin that failed our testing had met all established quality requirements, and shared knowledge from inside and exterior research indicating its quality. It stated it has not acquired any market issues associated to this batch.

In India, the world’s largest producer of generic drugs, questions have been raised over whether or not producers are correctly punished for producing drugs that aren’t match for goal – and whether or not international regulators have correct oversight.

“The Indian government’s interest is in trying to protect the industry,” stated public well being activist and former Big Pharma whistleblower Dinesh Thakur.

Sixteen of the 17 producers recognized on this investigation are based mostly in India, and 5 have been beforehand flagged by a regulator for producing substandard batches of drugs. One of them, Zee Laboratories, has been flagged 46 occasions since 2018. 

India’s drug regulator informed TBIJ that Zee Laboratories has been audited and given a “stop production order”, which was lifted after the corporate resolved the issues in query. It didn’t give particulars about when this was, which points it pertained to or whether or not the corporate confronted any penalties. 

It’s additionally unclear whether or not the producers uncovered in TBIJ’s earlier investigation into substandard asparaginase have confronted any repercussions, regardless of 70,000 kids with leukaemia being in danger. 

Three of these firms – Getwell Pharmaceuticals, United Biotech and VHB Medi Sciences – additionally made a few of the substandard drugs revealed by this investigation.

Thakur stated there’s just one approach to clarify the manufacturing of weak drugs by massive firms: “Somebody’s cutting corners.”

Meanwhile, these medicines proceed to fill pharmacy cabinets. Zuvius Lifesciences and GLS Pharma have provided their failed manufacturers to over 40 international locations. And prior to now two years, Venus Remedies – which made the drug that pharmacists stated wasn’t price prescribing – has been awarded a collection of contracts and licences, together with from the Pan American Health Organization to provide a number of important most cancers drugs to Latin American international locations.

India’s drug regulator defended the oversight system, saying that failing drugs are recalled and producers face “either administrative penalties or legal prosecution in court”. 

Getwell Pharmaceuticals, GLS Pharma, VHB Medi Sciences, and Zee Laboratories didn’t reply to a number of requests for remark.

Shortage of assets

In order to make sure that folks the world over have entry to secure, efficient drugs, the World Health Organization (WHO) has put in place a collection of steps. It has compiled a listing of “essential medicines”, to assist international locations with restricted assets know what to prioritise. It checks sure drugs, lively components and their producers to create a pre-approved record that international locations can belief. 

The WHO additionally oversees a set of requirements for producers and drugs that many international locations discuss with when importing medicines.

However, these measures have their very own limitations.

The record of really helpful medicines, for instance, solely expanded to incorporate most cancers drugs in 2019 and consultants say WHO ought to embrace extra of them on the record. Shalini Jayasekar-Zürn of the Union for International Cancer Control, a worldwide membership organisation devoted to taking motion on most cancers, says it presently solely encompasses two most cancers drugs, rituximab and trastuzumab. “It would be great if the list was expanded to include more essential medicines, especially for cancer,” she stated.

While the WHO oversees requirements for producers and drugs, it’s as much as the international locations shopping for medicines to verify these requirements are met – which isn’t any simple activity given the assets of nationwide regulators. 

Meanwhile, Thakur stated that one WHO scheme – a certificates system that claims a given drug meets varied requirements – has been undermined by firms which have discovered “workarounds” to pay money for the paperwork with out bettering quality. “It’s not worth the paper it’s written on,” he stated. 

The upshot, consultants say, is that with out the great oversight seen in international locations just like the UK, the WHO’s processes don’t cease substandard medicines making their approach onto cabinets.

Reflecting on TBIJ’s findings alongside his personal expertise, Thakur stated that the WHO was “clearly not” delivering on its said goal: to advertise well being, maintain the world secure and serve the susceptible.

The WHO didn’t reply to a number of requests for remark made by TBIJ.

A excessive worth

The merciless irony is that on this race to the underside, it’s the most cancers sufferers who are sometimes left to foot the invoice. And those that have the least pay essentially the most: in low revenue international locations, the price of 58% of important most cancers medicines is paid by sufferers, in contrast with 1.8% in upper-middle-income international locations. 

One most cancers pharmacist in Ethiopia estimated that it might take over a 12 months for a affected person to avoid wasting for most cancers remedy. If that medication then seems to be defective, they merely may not be capable to afford to pay for one more. 

“Most people believe cancer is incurable,” they stated. “When they end up with a medicine that won’t cure them, that’s another tragedy.”

“For me, it’s a question of fairness,” stated Lieberman, the lead researcher. “[Patients] have the right to be treated with a medicine that actually is what it says it is. One that has the correct ingredients in it, that hasn’t degraded, and that doesn’t have things in it that will hurt them. It’s too important.”

* The Access to Medicine Foundation is part-funded by the Bill & Melinda Gates Foundation, considered one of TBIJ’s funders. None of the Bureau’s funders has any say in its editorial selections.

This article is collectively revealed by The Hindu and TBIJ.